Journal
FUTURE ONCOLOGY
Volume 15, Issue 32, Pages 3665-3674Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/fon-2019-0433
Keywords
adjuvant; Daromun; IL-2; immunotherapy; intralesional therapy; L19; melanoma; neoadjuvant; surgery; TNF
Categories
Ask authors/readers for more resources
High-risk resectable melanoma poses therapeutic challenges as this subgroup remains most vulnerable for disease recurrence. Immunotherapy has established its efficacy in cases of advanced melanoma, and now is actively being investigated in the multimodal management of resectable disease. Daromun, an intralesional immunocytokine, has emerged as a unique immunotherapy in its ability to preferentially target tumor cells, resulting in direct destruction, while generating a bystander effect that leads to a distant treatment effect. On the basis of its mechanism of action, there is growing interest in delivering immune-based therapies in a neoadjuvant setting. In this review, the neo-DREAM study, a Phase III trial comparing the safety and efficacy of neoadjuvant Daromun for resectable stage IIIB/C melanoma will be described. Clinical Trial Registration Number: NCT03567889
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available